News

Further data could back zanidatamab as advanced treatment for HER2-positive advanced gastroesophageal adenocarcinoma.
Panelists discuss how comprehensive patient education about expected adverse effects, combined with prophylactic measures ...
Step-up dosing with remote monitoring resulted in 47% of patients receiving bispecific antibodies remaining outpatient, even ...